Design and optimisation of dendrimer-conjugated Bcl-2/x

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

51 citing papers in PubMed, 90 citations in OpenAlex.

1. From Platelet Toxicity to Precision Targeting: Evolving Strategies to Overcome Thrombocytopenia in BCL-2/BCL-XL Inhibition.Health science reports · 2026
   Article
2. Therapeutic potential of BH3-mimetics and NK cell-mediated immunotherapy in T-ALL.Cell death & disease · 2026
   Article
3. Revealing the Binding Mechanism of Gossypol on Bcl‑2 via Funnel Metadynamics Simulations.ACS omega · 2026
   Article
4. BCL-2 and BCL-xL in Cancer: Regulation, Function, and Therapeutic Targeting.International journal of molecular sciences · 2026
   Review
5. Dual Bcl-2/Bcl-xl inhibition via AZD0466 combines with immune checkpoint blockade to enhance anti-tumour activity.Cell death & disease · 2026
   Article
6. Nanotechnology-Driven Cancer Therapies for Precision Oncology: Advances and Clinical Outlook.International journal of nanomedicine · 2026
   Review
7. Therapy-Induced Senescence (TIS) and SASP: The p53-Mediated Interplay in Cancer Progression and Treatment.International journal of molecular sciences · 2025
   Review
8. The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy.Signal transduction and targeted therapy · 2025
   Review
9. Antileukemia efficacy of the dual BCL2/BCL-XL inhibitor AZD0466 in acute lymphoblastic leukemia preclinical models.Blood advances · 2025
   Article
10. How Dendrimers Impact Fibrin Clot Formation, Structure, and Properties.ACS omega · 2024
    Article
11. The dual BCL-2 and BCL-XL inhibitor AZD4320 acts on-target and synergizes with MCL-1 inhibition in B-cell precursor ALL.Blood advances · 2024
    Article
12. Overcoming Cancer Drug Resistance with Nanoparticle Strategies for Key Protein Inhibition.Molecules (Basel, Switzerland) · 2024
    Review
13. Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia.Cell death & disease · 2024
    Review
14. Directly targeting BAX for drug discovery: Therapeutic opportunities and challenges.Acta pharmaceutica Sinica. B · 2024
    Review
15. Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2.Journal of medicinal chemistry · 2024
    Article
16. BCL-XCell death & disease · 2024
    Article
17. PEGylated therapeutics in the clinic.Bioengineering & translational medicine · 2024
    Review
18. The Role of t(11;14) in Tailoring Treatment Decisions in Multiple Myeloma.Cancers · 2023
    Review
19. Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers.Cancers · 2023
    Review
20. Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

31 authors at 3 institutions in 5 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as